Read the rest here:
Dogecoin Cash, Inc. Subsidiary PrestoDoctor Launches April Promotion Offering 42.0% Off Medical Cannabis Evaluations
Related Post
- Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - April 8th, 2025
- SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML - April 8th, 2025
- General Oncology Appoints Seasoned Biotech Executive Abid Ansari as Chief Financial Officer - April 8th, 2025
- AscellaHealth Showcases Rare Disease Expertise and Comprehensive Specialty Pharmaceutical Solutions at World Orphan Drug Congress USA 2025 - April 8th, 2025
- Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order - April 8th, 2025
- Better Choice Company Revises Payment Date for Stock Dividend of 0.35 per Share for Each Share Held for Stockholders of Record as of April 17, 2025 - April 8th, 2025
- Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting - April 8th, 2025
- Neurona Therapeutics Presents Positive Clinical Data Update from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at American Academy of... - April 8th, 2025
- Ipsen publishes its 2024 Universal Registration Document - April 8th, 2025
- Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis - April 8th, 2025
- Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference - April 8th, 2025
- BON Announces Unlocking Broccoli's Nutritional Power: Advanced Delivery System for Glucoraphanin Activation - April 8th, 2025
- Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update - April 8th, 2025
- Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at... - April 8th, 2025
- Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities - April 8th, 2025
- Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - April 8th, 2025
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025 - April 8th, 2025
- Myriad Genetics Announces Inducement Awards - April 8th, 2025
- Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease - April 8th, 2025
- Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs - April 8th, 2025
- I-Mab Reports Full Year 2024 Financial Results and Provides Business Update - April 6th, 2025
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 6th, 2025
- Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - April 6th, 2025
- Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update - April 6th, 2025
- Vaxil: Management and Operational Update - April 6th, 2025
- Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 6th, 2025
- Edesa Biotech Announces Chief Financial Officer Transition - April 6th, 2025
- Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger - April 6th, 2025
- AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - April 6th, 2025
- Arialief Reviews (SHOCKING REPORT!) Is This Sciatic Nerve Relief Supplement Safe or Overhyped Hoax? - April 6th, 2025
- Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update - April 4th, 2025
- Praxis Precision Medicines to Participate in Upcoming April Conferences - April 4th, 2025
- Anne Whitaker Appointed as Non-Executive Director - April 4th, 2025
- Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN)... - April 4th, 2025
- Zelluna ASA [ZLNA]: Notice of Annual General Meeting on April 29, 2025 - April 4th, 2025
- Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs - April 4th, 2025
- New LabTAG Add-On Streamlines Laboratory Labeling with Dymo® LabelWriter™ 5-Series and eLabNext Integration - April 4th, 2025
- Verano to Report First Quarter 2025 Financial Results on May 8, 2025 - April 4th, 2025
- AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States - April 4th, 2025
- NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - April 4th, 2025
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 4th, 2025
- Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral... - April 4th, 2025
- Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee - April 4th, 2025
- Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease - April 4th, 2025
- NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement - April 4th, 2025
- Better Choice Company Signs Definitive Agreement for SRx Health Solutions to Convert CAD$4 Million in Debt to Equity - April 4th, 2025
- Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider - April 4th, 2025
- Renovaro Provides Update to Definitive Agreement with Predictive Oncology - April 4th, 2025
- Better Choice Company Chairman Provides Shareholder Update on SRx Health Acquisition and Comments on Recent Debt-to-Equity Transaction - April 4th, 2025
- Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference - April 1st, 2025
- Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia - April 1st, 2025
- Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings - April 1st, 2025
- Aruna’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, Inducted into the 2025 Class of the American Institute for Medical and Biological... - April 1st, 2025
- Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - April 1st, 2025
- Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update - April 1st, 2025
- Revolution Medicines to Participate in April 2025 Investor Conferences - April 1st, 2025
- Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled... - April 1st, 2025
- Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights - April 1st, 2025
- Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates - April 1st, 2025
- Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights - April 1st, 2025
- Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights - April 1st, 2025
- Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - April 1st, 2025
- Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update - April 1st, 2025
- Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - April 1st, 2025
- ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - April 1st, 2025
- ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - April 1st, 2025
- Total number of shares and voting rights in Zealand Pharma as of March 31, 2025 - April 1st, 2025
- Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine - April 1st, 2025
- Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order - April 1st, 2025
- Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 - March 30th, 2025
- Tr1X Announces Succession Plan: Appoints David de Vries CEO, Effective June 1; Bill Lis to Serve as Executive Chairman - March 30th, 2025
- Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of... - March 30th, 2025
- Intelligent Bio Solutions to Highlight Proprietary Drug Testing Technology at 2025 NDASA Conference and Trade Show - March 30th, 2025
- Aptose Reports Year End 2024 Results and Corporate Highlights - March 30th, 2025
- Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates - March 30th, 2025
- Strategic update on the progress and development of Molecure's key clinical projects in 2024 - March 30th, 2025
- FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate... - March 30th, 2025
- NTG Nordic Transport Group A/S – Annual General Meeting 2025 - March 30th, 2025
- Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates - March 30th, 2025
- HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results - March 30th, 2025
Recent Comments